Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Acelrx Pharmaceutica (ACRX)

Acelrx Pharmaceutica (ACRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
AcelRx Pharmaceuticals: Q3 Earnings Snapshot

AcelRx Pharmaceuticals: Q3 Earnings Snapshot

ACRX : 0.8600 (+7.50%)
AcelRx Receives IDE Approval for Niyad and Advances to a Single Registration Study

/PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of...

ACRX : 0.8600 (+7.50%)
AcelRx Pharmaceuticals: Q2 Earnings Snapshot

AcelRx Pharmaceuticals: Q2 Earnings Snapshot

ACRX : 0.8600 (+7.50%)
AcelRx Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Capital raise closed in July, led by new healthcare investors; provides access to up to $26.3 million in capital, with $10 million immediately available AcelRx...

ACRX : 0.8600 (+7.50%)
AcelRx to Host Second Quarter 2023 Financial Results Call and Webcast on August 10, 2023

/PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of...

ACRX : 0.8600 (+7.50%)
AcelRx Pharmaceuticals Announces Closing of Previously Announced Private Placement Priced At-The-Market Under Nasdaq Rules

/PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx" or the "Company"), a specialty pharmaceutical company focused on the development and...

ACRX : 0.8600 (+7.50%)
AcelRx Pharmaceuticals Announces $10 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules

/PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx" or the "Company"), a specialty pharmaceutical company focused on the development and...

ACRX : 0.8600 (+7.50%)
AcelRx Pharmaceuticals (ACRX) Reports Break-Even Earnings for Q1

AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 100% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

ACRX : 0.8600 (+7.50%)
BVS : 3.97 (+0.25%)
AcelRx Pharmaceuticals: Q1 Earnings Snapshot

AcelRx Pharmaceuticals: Q1 Earnings Snapshot

ACRX : 0.8600 (+7.50%)
AcelRx Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

/PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of...

ACRX : 0.8600 (+7.50%)

Barchart Exclusives

Earnings, the Yen and Other Key Things to Watch This Week
This week is relatively quiet on the news front, but there are still earnings due out and plenty of other macro factors to watch. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar